rewirebio.iobenchmarks
Source

Biology-in-the-loop: Amortized Adaptive Hit Discovery in CRISPR Screens

arXiv:2609.11877 version 1, submitted 2026-09-10; not peer reviewed · Preprint

DOI: 10.48550/arXiv.2609.11877Original source

Authors are at Genentech. Two of them (De Brouwer, Scalia) are also authors of AssayBench (tgtval-20261009-source-debrouwer2026), on which AssayBench-Loop is built.

What this source contributed

Records in this release that cite this source. A record can cite several sources.

Results

Values as the source printed them. Compare results only under compatible protocols, datasets and metrics.

Model or configurationMetricValueDatasetEvaluation
AssayFormer (BPMF embeddings, supervised then GRPO) (AssayBench-Loop)Annotation overlap ratio (mean pairwise Jaccard overlap of GO biological-process annotations within a batch, divided by that of an equal-size random batch from the screen library, averaged over batches; mean over the 20 AssayBench-Loop test screens)2.38 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer (BPMF embeddings, supervised then GRPO) on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer (BPMF embeddings, supervised then GRPO) (AssayBench-Loop)Effective number of groups (EP-B: Hill number of order 1 at batch scope, rarefied to 30 annotated genes per batch, one random group per gene per draw, 400 Monte Carlo draws, averaged within each screen then across the 20 test screens; not comparable with EP-S or EP-D)19.3 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer (BPMF embeddings, supervised then GRPO) on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer (BPMF embeddings, supervised then GRPO) (AssayBench-Loop)Effective number of groups (EP-D: Hill number of order 1 at dataset scope, rarefied to 6,000 annotated genes across the complete test set, one random group per gene per draw, 300 Monte Carlo draws; not comparable with EP-B or EP-S)65.0 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer (BPMF embeddings, supervised then GRPO) on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer (BPMF embeddings, supervised then GRPO) (AssayBench-Loop)Effective number of groups (EP-S: Hill number of order 1 at screen scope, rarefied to 200 annotated genes per screen, one random group per gene per draw, 400 Monte Carlo draws, averaged across the 20 test screens; not comparable with EP-B or EP-D)46.7 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer (BPMF embeddings, supervised then GRPO) on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer (BPMF embeddings, supervised then GRPO) (AssayBench-Loop)Hit enrichment factor (hits found divided by hits expected under random selection, after 10 rounds of 100 genes; hallucinated genes and unfilled slots count in the denominator, valid genes outside the screen library do not; mean over the 20 AssayBench-Loop test screens)4.83 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer (BPMF embeddings, supervised then GRPO) on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer (BPMF embeddings, supervised then GRPO) (AssayBench-Loop)Normalized cumulative hits AUC (area under the fraction-of-hits against fraction-of-library-queried curve over 10 rounds, divided by an oracle's area over the same effective budget; mean over the 20 AssayBench-Loop test screens)17.2 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer (BPMF embeddings, supervised then GRPO) on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer (BPMF embeddings, supervised then GRPO) (AssayBench-Loop)Proportion (share of acquired hits that are DepMap common-essential genes (1,827 genes); mean over the 20 AssayBench-Loop test screens)40.7 percentAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer (BPMF embeddings, supervised then GRPO) on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer (BPMF embeddings, supervised then GRPO) (AssayBench-Loop)Proportion (shortfall: share of acquired genes outside the screen library, including hallucinated gene names; mean over the 20 AssayBench-Loop test screens)10.0 percentAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer (BPMF embeddings, supervised then GRPO) on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer (BPMF embeddings, supervised then GRPO) (AssayBench-Loop)Recall (fraction of the screen's hits acquired within 10 rounds of 100 genes (FH); mean over the 20 AssayBench-Loop test screens)23.2 percentAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer (BPMF embeddings, supervised then GRPO) on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer (BPMF embeddings, supervised then GRPO) (AssayBench-Loop)Vendi ratio (Vendi score of each batch under a cosine kernel on GenePT embeddings, divided by batch size and averaged over batches; mean over the 20 AssayBench-Loop test screens)55.9 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer (BPMF embeddings, supervised then GRPO) on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, GRPO with terminal-EF reward (AssayBench-Loop)Annotation overlap ratio (mean pairwise Jaccard overlap of GO biological-process annotations within a batch, divided by that of an equal-size random batch from the screen library, averaged over batches; mean over the 20 AssayBench-Loop test screens)2.35 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, GRPO with terminal-EF reward on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, GRPO with terminal-EF reward (AssayBench-Loop)Effective number of groups (EP-B: Hill number of order 1 at batch scope, rarefied to 30 annotated genes per batch, one random group per gene per draw, 400 Monte Carlo draws, averaged within each screen then across the 20 test screens; not comparable with EP-S or EP-D)19.0 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, GRPO with terminal-EF reward on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, GRPO with terminal-EF reward (AssayBench-Loop)Effective number of groups (EP-D: Hill number of order 1 at dataset scope, rarefied to 6,000 annotated genes across the complete test set, one random group per gene per draw, 300 Monte Carlo draws; not comparable with EP-B or EP-S)62.7 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, GRPO with terminal-EF reward on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, GRPO with terminal-EF reward (AssayBench-Loop)Effective number of groups (EP-S: Hill number of order 1 at screen scope, rarefied to 200 annotated genes per screen, one random group per gene per draw, 400 Monte Carlo draws, averaged across the 20 test screens; not comparable with EP-B or EP-D)45.0 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, GRPO with terminal-EF reward on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, GRPO with terminal-EF reward (AssayBench-Loop)Hit enrichment factor (hits found divided by hits expected under random selection, after 10 rounds of 100 genes; hallucinated genes and unfilled slots count in the denominator, valid genes outside the screen library do not; mean over the 20 AssayBench-Loop test screens)4.29 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, GRPO with terminal-EF reward on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, GRPO with terminal-EF reward (AssayBench-Loop)Normalized cumulative hits AUC (area under the fraction-of-hits against fraction-of-library-queried curve over 10 rounds, divided by an oracle's area over the same effective budget; mean over the 20 AssayBench-Loop test screens)14.9 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, GRPO with terminal-EF reward on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, GRPO with terminal-EF reward (AssayBench-Loop)Proportion (share of acquired hits that are DepMap common-essential genes (1,827 genes); mean over the 20 AssayBench-Loop test screens)48.4 percentAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, GRPO with terminal-EF reward on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, GRPO with terminal-EF reward (AssayBench-Loop)Proportion (shortfall: share of acquired genes outside the screen library, including hallucinated gene names; mean over the 20 AssayBench-Loop test screens)10.7 percentAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, GRPO with terminal-EF reward on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, GRPO with terminal-EF reward (AssayBench-Loop)Recall (fraction of the screen's hits acquired within 10 rounds of 100 genes (FH); mean over the 20 AssayBench-Loop test screens)20.5 percentAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, GRPO with terminal-EF reward on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, GRPO with terminal-EF reward (AssayBench-Loop)Vendi ratio (Vendi score of each batch under a cosine kernel on GenePT embeddings, divided by batch size and averaged over batches; mean over the 20 AssayBench-Loop test screens)54.2 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, GRPO with terminal-EF reward on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, GRPO, no screen description (AssayBench-Loop)Annotation overlap ratio (mean pairwise Jaccard overlap of GO biological-process annotations within a batch, divided by that of an equal-size random batch from the screen library, averaged over batches; mean over the 20 AssayBench-Loop test screens)2.55 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, GRPO, no screen description on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, GRPO, no screen description (AssayBench-Loop)Effective number of groups (EP-B: Hill number of order 1 at batch scope, rarefied to 30 annotated genes per batch, one random group per gene per draw, 400 Monte Carlo draws, averaged within each screen then across the 20 test screens; not comparable with EP-S or EP-D)18.7 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, GRPO, no screen description on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, GRPO, no screen description (AssayBench-Loop)Effective number of groups (EP-D: Hill number of order 1 at dataset scope, rarefied to 6,000 annotated genes across the complete test set, one random group per gene per draw, 300 Monte Carlo draws; not comparable with EP-B or EP-S)63.1 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, GRPO, no screen description on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, GRPO, no screen description (AssayBench-Loop)Effective number of groups (EP-S: Hill number of order 1 at screen scope, rarefied to 200 annotated genes per screen, one random group per gene per draw, 400 Monte Carlo draws, averaged across the 20 test screens; not comparable with EP-B or EP-D)45.7 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, GRPO, no screen description on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, GRPO, no screen description (AssayBench-Loop)Hit enrichment factor (hits found divided by hits expected under random selection, after 10 rounds of 100 genes; hallucinated genes and unfilled slots count in the denominator, valid genes outside the screen library do not; mean over the 20 AssayBench-Loop test screens)4.52 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, GRPO, no screen description on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, GRPO, no screen description (AssayBench-Loop)Normalized cumulative hits AUC (area under the fraction-of-hits against fraction-of-library-queried curve over 10 rounds, divided by an oracle's area over the same effective budget; mean over the 20 AssayBench-Loop test screens)16.2 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, GRPO, no screen description on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, GRPO, no screen description (AssayBench-Loop)Proportion (share of acquired hits that are DepMap common-essential genes (1,827 genes); mean over the 20 AssayBench-Loop test screens)42.5 percentAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, GRPO, no screen description on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, GRPO, no screen description (AssayBench-Loop)Proportion (shortfall: share of acquired genes outside the screen library, including hallucinated gene names; mean over the 20 AssayBench-Loop test screens)5.9 percentAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, GRPO, no screen description on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, GRPO, no screen description (AssayBench-Loop)Recall (fraction of the screen's hits acquired within 10 rounds of 100 genes (FH); mean over the 20 AssayBench-Loop test screens)22.4 percentAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, GRPO, no screen description on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, GRPO, no screen description (AssayBench-Loop)Vendi ratio (Vendi score of each batch under a cosine kernel on GenePT embeddings, divided by batch size and averaged over batches; mean over the 20 AssayBench-Loop test screens)57.7 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, GRPO, no screen description on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, supervised only (AssayBench-Loop)Annotation overlap ratio (mean pairwise Jaccard overlap of GO biological-process annotations within a batch, divided by that of an equal-size random batch from the screen library, averaged over batches; mean over the 20 AssayBench-Loop test screens)2.54 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, supervised only on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, supervised only (AssayBench-Loop)Effective number of groups (EP-B: Hill number of order 1 at batch scope, rarefied to 30 annotated genes per batch, one random group per gene per draw, 400 Monte Carlo draws, averaged within each screen then across the 20 test screens; not comparable with EP-S or EP-D)18.3 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, supervised only on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, supervised only (AssayBench-Loop)Effective number of groups (EP-D: Hill number of order 1 at dataset scope, rarefied to 6,000 annotated genes across the complete test set, one random group per gene per draw, 300 Monte Carlo draws; not comparable with EP-B or EP-S)56.9 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, supervised only on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, supervised only (AssayBench-Loop)Effective number of groups (EP-S: Hill number of order 1 at screen scope, rarefied to 200 annotated genes per screen, one random group per gene per draw, 400 Monte Carlo draws, averaged across the 20 test screens; not comparable with EP-B or EP-D)42.7 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, supervised only on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, supervised only (AssayBench-Loop)Hit enrichment factor (hits found divided by hits expected under random selection, after 10 rounds of 100 genes; hallucinated genes and unfilled slots count in the denominator, valid genes outside the screen library do not; mean over the 20 AssayBench-Loop test screens)3.83 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, supervised only on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, supervised only (AssayBench-Loop)Normalized cumulative hits AUC (area under the fraction-of-hits against fraction-of-library-queried curve over 10 rounds, divided by an oracle's area over the same effective budget; mean over the 20 AssayBench-Loop test screens)13.2 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, supervised only on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, supervised only (AssayBench-Loop)Proportion (share of acquired hits that are DepMap common-essential genes (1,827 genes); mean over the 20 AssayBench-Loop test screens)37.5 percentAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, supervised only on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, supervised only (AssayBench-Loop)Proportion (shortfall: share of acquired genes outside the screen library, including hallucinated gene names; mean over the 20 AssayBench-Loop test screens)10.2 percentAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, supervised only on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, supervised only (AssayBench-Loop)Recall (fraction of the screen's hits acquired within 10 rounds of 100 genes (FH); mean over the 20 AssayBench-Loop test screens)18.3 percentAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, supervised only on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, supervised only (AssayBench-Loop)Vendi ratio (Vendi score of each batch under a cosine kernel on GenePT embeddings, divided by batch size and averaged over batches; mean over the 20 AssayBench-Loop test screens)52.5 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, supervised only on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, supervised only, no screen description (AssayBench-Loop)Annotation overlap ratio (mean pairwise Jaccard overlap of GO biological-process annotations within a batch, divided by that of an equal-size random batch from the screen library, averaged over batches; mean over the 20 AssayBench-Loop test screens)2.68 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, supervised only, no screen description on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, supervised only, no screen description (AssayBench-Loop)Effective number of groups (EP-B: Hill number of order 1 at batch scope, rarefied to 30 annotated genes per batch, one random group per gene per draw, 400 Monte Carlo draws, averaged within each screen then across the 20 test screens; not comparable with EP-S or EP-D)18.8 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, supervised only, no screen description on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, supervised only, no screen description (AssayBench-Loop)Effective number of groups (EP-D: Hill number of order 1 at dataset scope, rarefied to 6,000 annotated genes across the complete test set, one random group per gene per draw, 300 Monte Carlo draws; not comparable with EP-B or EP-S)56.5 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, supervised only, no screen description on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, supervised only, no screen description (AssayBench-Loop)Effective number of groups (EP-S: Hill number of order 1 at screen scope, rarefied to 200 annotated genes per screen, one random group per gene per draw, 400 Monte Carlo draws, averaged across the 20 test screens; not comparable with EP-B or EP-D)43.2 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, supervised only, no screen description on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, supervised only, no screen description (AssayBench-Loop)Hit enrichment factor (hits found divided by hits expected under random selection, after 10 rounds of 100 genes; hallucinated genes and unfilled slots count in the denominator, valid genes outside the screen library do not; mean over the 20 AssayBench-Loop test screens)3.82 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, supervised only, no screen description on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, supervised only, no screen description (AssayBench-Loop)Normalized cumulative hits AUC (area under the fraction-of-hits against fraction-of-library-queried curve over 10 rounds, divided by an oracle's area over the same effective budget; mean over the 20 AssayBench-Loop test screens)13.1 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, supervised only, no screen description on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, supervised only, no screen description (AssayBench-Loop)Proportion (share of acquired hits that are DepMap common-essential genes (1,827 genes); mean over the 20 AssayBench-Loop test screens)62.6 percentAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, supervised only, no screen description on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, supervised only, no screen description (AssayBench-Loop)Proportion (shortfall: share of acquired genes outside the screen library, including hallucinated gene names; mean over the 20 AssayBench-Loop test screens)5.1 percentAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, supervised only, no screen description on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, supervised only, no screen description (AssayBench-Loop)Recall (fraction of the screen's hits acquired within 10 rounds of 100 genes (FH); mean over the 20 AssayBench-Loop test screens)19.1 percentAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, supervised only, no screen description on AssayBench-Loop test (Edwards et al. 2026)
AssayFormer, BPMF embeddings, supervised only, no screen description (AssayBench-Loop)Vendi ratio (Vendi score of each batch under a cosine kernel on GenePT embeddings, divided by batch size and averaged over batches; mean over the 20 AssayBench-Loop test screens)56.7 unitlessAssayBench-Loop test split (20 genome-wide CRISPR screens published after 2021)AssayFormer, BPMF embeddings, supervised only, no screen description on AssayBench-Loop test (Edwards et al. 2026)

Claims

Statements this source supports, each with where in the source it was checked.

  • composition (assaybench-loop-composition): Composition AssayBench-Loop comprises 1,389 CRISPR screens across five phenotype categories, split temporally into 1,349 training (before 2021), 20 validation (2021) and 20 test (after 2021) screens; median test-to-training hit-set Jaccard similarity 0.064. (Section 2.1; Figure 2B caption)
  • Evidence summary: Select perturbations for a defined cellular response: Summary The evidence comes from one prospective challenge and two retrospective replays, which measure different things. In the Cancer Immunotherapy Data Science Challenge, scored prospectively in mouse T cells, the 20 original Challenge 2 submissions had a top-k overlap AUC of 0.452 to 0.566, with 17 of the 20 between 0.50 and 0.57; a random ordering is expected to score 0.5. That score is not a ROC AUC, and the genes it scores were drawn from the leading Challenge 1 nominations. In the follow-up, two nominated targets exceeded the Screen 1 targets on the immune checkpoint blockade objective; the source reports 61 nominations, 57 selected targets, 59 screen-2 genes and 50 perturbations passing quality control without reconciling them, so no success fraction follows. AssayBench-Loop replays 20 genome-wide CRISPR screens published after 2021, with each policy choosing 10 rounds of 100 genes. One random draw found 4.9% of each screen's hits on average (enrichment 1.04 over the random expectation). Language models used directly as the policy, with hit labels, reached enrichment of 1.39 to 4.81, BPMF 4.49, and the authors' handoffs from a language model to their AssayFormer up to 5.67, with the Gemini-3.1-Pro handoff finding 27.7% of hits. Many recovered hits are common-essential genes: 30.1% for that handoff, 18.6% for the random draw and 99.1% for a baseline that picks earlier screens' hits. Test screens were kept only if the best language model already passed a performance floor on them, and the paper does not say whether the models saw the screens' publications in training. The authors ran every row, and no uncertainty is printed. For two-gene combinations, NAIAD's replay of four viability screens counted how many of each screen's 200 strongest pairs the model ranked in its top 200 after four rounds: 143.0, 141.7, 99.7 and 150.0 when it acquired the pairs with the largest predicted effect, against 93.3, 70.3, 38.7 and 81.3 when it acquired pairs uniformly at random (means of three replicates). That count includes pairs the model predicted but never measured, and the uniform arm still uses the model's ranking, so it is not the yield of testing random pairs. The challenge's submissions scored close to a random ordering, while in both replays the leading model-guided policies scored above the random or uniform arm; the two differ in endpoint, candidate set, setting and who ran them, so their results cannot be compared directly. No source compares a model shortlist with random selection prospectively at the same budget. (ucc-research-source-challenge-supp-s2: Supplementary Table S2, media-3.xlsx, sheet 'Challenge 1 & 2', column D rows 2 to 24; ucc-research-source-challenge-paper: Abstract and Results Figure 5; ucpheno-20261022-source-edwards2026: Table 1, rows 'Random', 'GPT-5.6 Sol', 'BPMF [41]', 'Gemini-3.1-Pro → AssayFormer', 'GPT-5.6 Sol → AssayFormer' and 'Prior hit baseline', columns 'EF', 'FH (%)' and '%ess (%)'; Methods 4.2 and Appendix A (test-screen criteria); Supplementary Table 4, Base LLMs group, column 'EF'; pheno-20261022-qin2025-source-pmlr: Table 4, rows 'NAIAD MPE' and 'NAIAD Uniform')
  • handoff (assayloop-handoff): Handoff A large language model acts as the acquisition policy for the first k rounds and AssayFormer for the remaining T - k rounds; k = 3 was selected on the validation set. (Section 2.2; Methods 4.6)
  • post_training (assayllm-training): Post training AssayLLM is Qwen3.6-27B supervised fine-tuned on GLM-5.1 acquisition trajectories from the training screens and then trained with GRPO; the authors report EF rising from 2.65 (base) to 3.56 (SFT) and 3.69 (SFT + GRPO). (Section 2.7; Figure 6 caption; Methods 4.7)
  • prospective_validation (prospective-validation): Prospective validation The authors state that AssayBench-Loop is a retrospective benchmark and that the policies remain to be validated prospectively in a live experimental loop. (Section 3 (Discussion), limitations paragraph)
  • Relevance of AssayBench-Loop adaptive hit discovery: 10 rounds of 100 genes on 20 held-out CRISPR screens to "Select perturbations for a defined cellular response": Assessed by AssayBench-Loop adaptive hit discovery: 10 rounds of 100 genes on 20 held-out CRISPR screens (ucpheno-20261022-source-edwards2026: Table 1 and caption; Supplementary Table 4; Methods 4.2 and 4.3; Appendix H; Discussion (limitations))
  • training (assayformer-training): Training Gene embeddings are initialised by BPMF on the training hit matrix; the policy is trained with binary cross-entropy on simulated partial histories, then fine-tuned with GRPO on full 10-round rollouts using a context-delta reward relative to a context-free reference policy. (Section 2.2; Figure 3C caption; Methods 4.5)

Models, benchmarks and other records

Models (10)

Methods (12)

Configurations (53)

Protocols (1)

Dataset subsets (1)

Baselines (1)

Evaluations (53)

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

22 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-10-23-5347695500ed
Property and statementOriginal source and locationReview and provenance
Access and reuse
CC-BY-4.0 permits redistribution of the article bytes.
Source metadata
Biology-in-the-loop: Amortized Adaptive Hit Discovery in CRISPR Screens

Original source ↗

No field-specific location recorded

Version: arXiv:2609.11877 version 1, submitted 2026-09-10; not peer reviewed
Retrieved: 2026-10-22T13:57:26Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.access_and_reuse

Source artifact SHA-256: adcaaa5b7f9bd0e3bc1f91d94d26c8d4924c5c0b3064b6625c01ba92c6eaef28

Hash scope: pdftotext -layout text layer, parsed by data/omics/use-case-refresh-phenotype-20261022/extract/edwards2026assayloop.py

Inspected artifact

Archive note
Not archived in the batch; the artifact_sha256 pins the bytes read. The digest matches the copy hashed for the 2026-10-07 dossier and the 2026-10-22 search pass.
Source metadata
Biology-in-the-loop: Amortized Adaptive Hit Discovery in CRISPR Screens

Original source ↗

No field-specific location recorded

Version: arXiv:2609.11877 version 1, submitted 2026-09-10; not peer reviewed
Retrieved: 2026-10-22T13:57:26Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.archive_note

Source artifact SHA-256: adcaaa5b7f9bd0e3bc1f91d94d26c8d4924c5c0b3064b6625c01ba92c6eaef28

Hash scope: pdftotext -layout text layer, parsed by data/omics/use-case-refresh-phenotype-20261022/extract/edwards2026assayloop.py

Inspected artifact

Artifact SHA-256
adcaaa5b7f9bd0e3bc1f91d94d26c8d4924c5c0b3064b6625c01ba92c6eaef28
Source metadata
Biology-in-the-loop: Amortized Adaptive Hit Discovery in CRISPR Screens

Original source ↗

No field-specific location recorded

Version: arXiv:2609.11877 version 1, submitted 2026-09-10; not peer reviewed
Retrieved: 2026-10-22T13:57:26Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_sha256

Source artifact SHA-256: adcaaa5b7f9bd0e3bc1f91d94d26c8d4924c5c0b3064b6625c01ba92c6eaef28

Hash scope: pdftotext -layout text layer, parsed by data/omics/use-case-refresh-phenotype-20261022/extract/edwards2026assayloop.py

Inspected artifact

Artifact url
https://arxiv.org/pdf/2609.11877v1
Source metadata
Biology-in-the-loop: Amortized Adaptive Hit Discovery in CRISPR Screens

Original source ↗

No field-specific location recorded

Version: arXiv:2609.11877 version 1, submitted 2026-09-10; not peer reviewed
Retrieved: 2026-10-22T13:57:26Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_url

Source artifact SHA-256: adcaaa5b7f9bd0e3bc1f91d94d26c8d4924c5c0b3064b6625c01ba92c6eaef28

Hash scope: pdftotext -layout text layer, parsed by data/omics/use-case-refresh-phenotype-20261022/extract/edwards2026assayloop.py

Inspected artifact

Doi
10.48550/arXiv.2609.11877
Source metadata
Biology-in-the-loop: Amortized Adaptive Hit Discovery in CRISPR Screens

Original source ↗

No field-specific location recorded

Version: arXiv:2609.11877 version 1, submitted 2026-09-10; not peer reviewed
Retrieved: 2026-10-22T13:57:26Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.doi

Source artifact SHA-256: adcaaa5b7f9bd0e3bc1f91d94d26c8d4924c5c0b3064b6625c01ba92c6eaef28

Hash scope: pdftotext -layout text layer, parsed by data/omics/use-case-refresh-phenotype-20261022/extract/edwards2026assayloop.py

Inspected artifact

Extraction method
pdftotext -layout text layer, parsed by data/omics/use-case-refresh-phenotype-20261022/extract/edwards2026assayloop.py
Source metadata
Biology-in-the-loop: Amortized Adaptive Hit Discovery in CRISPR Screens

Original source ↗

No field-specific location recorded

Version: arXiv:2609.11877 version 1, submitted 2026-09-10; not peer reviewed
Retrieved: 2026-10-22T13:57:26Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.extraction_method

Source artifact SHA-256: adcaaa5b7f9bd0e3bc1f91d94d26c8d4924c5c0b3064b6625c01ba92c6eaef28

Hash scope: pdftotext -layout text layer, parsed by data/omics/use-case-refresh-phenotype-20261022/extract/edwards2026assayloop.py

Inspected artifact

Licence
CC-BY-4.0
Source metadata
Biology-in-the-loop: Amortized Adaptive Hit Discovery in CRISPR Screens

Original source ↗

No field-specific location recorded

Version: arXiv:2609.11877 version 1, submitted 2026-09-10; not peer reviewed
Retrieved: 2026-10-22T13:57:26Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.licence

Source artifact SHA-256: adcaaa5b7f9bd0e3bc1f91d94d26c8d4924c5c0b3064b6625c01ba92c6eaef28

Hash scope: pdftotext -layout text layer, parsed by data/omics/use-case-refresh-phenotype-20261022/extract/edwards2026assayloop.py

Inspected artifact

Media type
application/pdf
Source metadata
Biology-in-the-loop: Amortized Adaptive Hit Discovery in CRISPR Screens

Original source ↗

No field-specific location recorded

Version: arXiv:2609.11877 version 1, submitted 2026-09-10; not peer reviewed
Retrieved: 2026-10-22T13:57:26Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.media_type

Source artifact SHA-256: adcaaa5b7f9bd0e3bc1f91d94d26c8d4924c5c0b3064b6625c01ba92c6eaef28

Hash scope: pdftotext -layout text layer, parsed by data/omics/use-case-refresh-phenotype-20261022/extract/edwards2026assayloop.py

Inspected artifact

Publication status
preprint
Source metadata
Biology-in-the-loop: Amortized Adaptive Hit Discovery in CRISPR Screens

Original source ↗

No field-specific location recorded

Version: arXiv:2609.11877 version 1, submitted 2026-09-10; not peer reviewed
Retrieved: 2026-10-22T13:57:26Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.publication_status

Source artifact SHA-256: adcaaa5b7f9bd0e3bc1f91d94d26c8d4924c5c0b3064b6625c01ba92c6eaef28

Hash scope: pdftotext -layout text layer, parsed by data/omics/use-case-refresh-phenotype-20261022/extract/edwards2026assayloop.py

Inspected artifact

Retrieved at
2026-10-22T13:57:26Z
Source metadata
Biology-in-the-loop: Amortized Adaptive Hit Discovery in CRISPR Screens

Original source ↗

No field-specific location recorded

Version: arXiv:2609.11877 version 1, submitted 2026-09-10; not peer reviewed
Retrieved: 2026-10-22T13:57:26Z

catalogued

No individual claim review recorded

Audit details

Field: attributes.retrieved_at

Source artifact SHA-256: adcaaa5b7f9bd0e3bc1f91d94d26c8d4924c5c0b3064b6625c01ba92c6eaef28

Hash scope: pdftotext -layout text layer, parsed by data/omics/use-case-refresh-phenotype-20261022/extract/edwards2026assayloop.py

Inspected artifact

How to read the evidence

Sources and history

Release 2026-10-23-5347695500ed · Record review: source checked

Preprint introducing the AssayBench-Loop benchmark of 1,389 historical CRISPR screens and the AssayLoop, AssayFormer and AssayLLM acquisition policies.

Release history

No supporting source is linked yet.

Read original source

Download this release (gzip)
Technical metadata and extraction receipts

Stable ID: ucpheno-20261022-source-edwards2026

areas
cells-tissues
contexts
research
url
https://arxiv.org/abs/2609.11877v1
artifact url
https://arxiv.org/pdf/2609.11877v1
version
arXiv:2609.11877 version 1, submitted 2026-09-10; not peer reviewed
retrieved at
2026-10-22T13:57:26Z
artifact sha256
adcaaa5b7f9bd0e3bc1f91d94d26c8d4924c5c0b3064b6625c01ba92c6eaef28
doi
10.48550/arXiv.2609.11877
publication status
preprint
licence
CC-BY-4.0
media type
application/pdf
source locator
Full artifact bytes; per-record locators on each record
access and reuse
CC-BY-4.0 permits redistribution of the article bytes.
archive note
Not archived in the batch; the artifact_sha256 pins the bytes read. The digest matches the copy hashed for the 2026-10-07 dossier and the 2026-10-22 search pass.
extraction method
pdftotext -layout text layer, parsed by data/omics/use-case-refresh-phenotype-20261022/extract/edwards2026assayloop.py
scope note
Authors are at Genentech. Two of them (De Brouwer, Scalia) are also authors of AssayBench (tgtval-20261009-source-debrouwer2026), on which AssayBench-Loop is built.
Related records

    Suggest a correction